Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Some LDP Members Keen to Tackle Kampo NHI Price Problem
January 21, 2015
-
REGULATORY R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
-
REGULATORY R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
-
REGULATORY PMDA Head Expresses Full Support for AMED
January 19, 2015
-
ORGANIZATION JPMA Notifies of Unfavorable Expressions for Disease Awareness Ads
January 16, 2015
-
ORGANIZATION Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading
January 15, 2015
-
INTERVIEW EFPIA Japan Chairman Says Drug Costs Won’t Explode
January 14, 2015
-
ORGANIZATION Wholesalers Must Revamp Biz Model to Cope with Change in Sales Mix: JPWA Chief
January 14, 2015
-
REGULATORY MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors
January 13, 2015
-
ORGANIZATION Price Grouping Rule Triggered “Distortion” in Generic Market: JGA President
January 9, 2015
-
REGULATORY 30% R&D Tax Deduction Cap Could Be Secured with Open Innovation Tax Break: Economic Affairs Division
January 8, 2015
-
REGULATORY Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau
January 7, 2015
-
REGULATORY Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions
January 6, 2015
-
ORGANIZATION FPMAJ Chairman Wishes for Good Environment for Drug Innovation in 2015
January 1, 2015
-
TRENDS ARBs at a Turning Point: Inroads by Generics to Lead to Gradual Decline in Sales
December 26, 2014
-
REGULATORY LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
-
ORGANIZATION FPMAJ “Hasn’t Given Up” on Maintenance of 30% R&D Tax Deduction Cap: Chairman
December 24, 2014
-
ORGANIZATION EFPIA Japan Chairman Calls for More Rewards for Innovation
December 22, 2014
-
BUSINESS Takeda Names Sanofi’s Plump as New R&D Head
December 19, 2014
-
BUSINESS Daiichi Sankyo Looks to Bring Annual 8-10 Projects into Clinical Phase, Open Innovation Key to Success: R&D Execs
December 18, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…